Attapon Cheepsattayakorn^1-4*, Ruangrong Cheepsattayakorn⁵ and Porntep Siriwanarangsun²

¹Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand
²Faculty of Medicine, Western University, Pathumtani Province, Thailand
³10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand
⁴Department of Disease Control, Ministry of Public Health, Thailand
⁵Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

*Corresponding Author: Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand.

Received: March 27, 2024; Published: April 01, 2024

Abstract

SARS-CoV-2 infectivity depends on binding its S protein with the entry-receptor “ hACE-2” a promising strategic treatment, therefore, is this interaction inhibition [1-3]. Some SARS-CoV-2 variants, such as B.1.1.7 (Alpha), B.1.617.2 (Delta), and B.1.1.529 (Omicron) variants were highly resistant to mRNA-1273 vaccine-induced humoral immunity or BNT162b2 [4-6]. A recent study demonstrated that in a female mouse model, inhalation of ACE-2-expressing-human-lung-spheroid-cells (LSC)-derived exosomes (LSC-Exo) (Figure 1) could protect the host throughout the whole lung by biodistribution and deposition against COVID-19 (SARS-CoV-2) infection by SARS-CoV-2 binding, blocking the interaction of host cells with SARS-CoV-2, and virus neutralization both in vitro and in vivo [7]. This study also revealed decrease of viral loads and protection of SARS-CoV-2-induced disease [7]. Three different types of inhalation devices are commonly used; jet, ultrasonic, and vibrating mesh (all are nebulizer) (Figure 2) [8]. In non-human primates and rats studies, when nebulized with eFlow, human immunoglobulin preparations were deposited into the airways as well as treated-lung alveoli [9]. VR942, an anti-interleukin (IL)-13 mAb is a first-in-class for dry-powder inhalers (DPIs)

References

1. Lan J. “Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE-2 receptor”. Nature 581 (2020): 215-220.
2. Huang X., et al. “Nanotechnology-based strategies against SARS-CoV-2 variants”. Nature Nanotechnology 17 (2022): 1027-1037.
3. Zhang L., et al. “An ACE-2 decoy can be administered by inhalation and potently targets omicron variants of SARS-CoV-2”. EMBO Molecular Medicine 14 (2022): e16109.
4. Garcia-Beltran WF., et al. “Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity”. Cell 184 (2021): 2372-2383.e2379.
5. Pouwels KB., et al. “Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK”. Nature Medicine 27 (2021): 2127-2135.
6. Hui KPY., et al. “SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo”. Nature 603 (2022): 715-720.
7. Wang Z., et al. “Inhalation of ACE-2-expressing lung exosomes provides prophylactic protection against SARS-CoV-2”. Nature Communications 15 (2024): 2236.
8. Moroni-Zengraf P., et al. “Inhalation devices”. Canadian Respiratory Journal (2018): 5642074.
9. Vonarburg C., et al. “Topical application of nebulized human IgG, IgA, and IgAM in the lungs of rats and non-human primates”. Respiratory Research 1 (2019): 99.
10. Burgess G., et al. “Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942”. EBioMedicine 35 (2018): 67-75.

Citation

Citation: Attapon Cheepsattayakorn., et al. “Prophylactic Protection Against COVID-19 By ACE-2-Expressing-Lung Exosomes Inhalation".Acta Scientific Microbiology 7.5 (2024): 01-03.

Copyright

Copyright: © 2024 Attapon Cheepsattayakorn., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.